bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Authors: Lheureux Stephanie , Prokopec Stephenie D. , Oldfield Leslie E. , Gonzalez-Ochoa Eduardo , Bruce Jeffrey P. , Wong Derek , Danesh Arnavaz , Torti Dax , Torchia Jonathan , Fortuna Alexander , Singh Sharanjit , Irving Matthew , Marsh Kayla , Lam Bernard , Speers Vanessa , Yosifova Aleksandra , Oaknin Ana , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , Oza Amit M. , Pugh Trevor J.
Published: September 2023

Supplementary Table S5: Novel pathogenic mutations discovered in cfDNA. List of novel pathogenic mutations found in cfDNA samples that were not detected in the bulk tumour tissue by whole exome sequencing. For each mutation, both the variant allele frequency (VAF), median fragment size and total fragment count for ALT and REF reads (only available for SNVs), and inferred status (somatic or CHIP mutation) are shown.
Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Authors: Lheureux Stephanie , Prokopec Stephenie D. , Oldfield Leslie E. , Gonzalez-Ochoa Eduardo , Bruce Jeffrey P. , Wong Derek , Danesh Arnavaz , Torti Dax , Torchia Jonathan , Fortuna Alexander , Singh Sharanjit , Irving Matthew , Marsh Kayla , Lam Bernard , Speers Vanessa , Yosifova Aleksandra , Oaknin Ana , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , Oza Amit M. , Pugh Trevor J.
Published: September 2023

Supplementary Table S3: Targeted Sequencing Panel. List of regions included in the CHARM+EVOLVE panel used for targeted sequencing; coordinates are for human reference hg38.
Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Authors: Lheureux Stephanie , Prokopec Stephenie D. , Oldfield Leslie E. , Gonzalez-Ochoa Eduardo , Bruce Jeffrey P. , Wong Derek , Danesh Arnavaz , Torti Dax , Torchia Jonathan , Fortuna Alexander , Singh Sharanjit , Irving Matthew , Marsh Kayla , Lam Bernard , Speers Vanessa , Yosifova Aleksandra , Oaknin Ana , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , Oza Amit M. , Pugh Trevor J.
Published: September 2023

Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.
Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Authors: Lheureux Stephanie , Prokopec Stephenie D. , Oldfield Leslie E. , Gonzalez-Ochoa Eduardo , Bruce Jeffrey P. , Wong Derek , Danesh Arnavaz , Torti Dax , Torchia Jonathan , Fortuna Alexander , Singh Sharanjit , Irving Matthew , Marsh Kayla , Lam Bernard , Speers Vanessa , Yosifova Aleksandra , Oaknin Ana , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , Oza Amit M. , Pugh Trevor J.
Published: September 2023

Supplementary Table S1: Representativeness of Study Participants
Supplementary Figure S6 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Authors: Lheureux Stephanie , Prokopec Stephenie D. , Oldfield Leslie E. , Gonzalez-Ochoa Eduardo , Bruce Jeffrey P. , Wong Derek , Danesh Arnavaz , Torti Dax , Torchia Jonathan , Fortuna Alexander , Singh Sharanjit , Irving Matthew , Marsh Kayla , Lam Bernard , Speers Vanessa , Yosifova Aleksandra , Oaknin Ana , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , Oza Amit M. , Pugh Trevor J.
Published: September 2023

Supplementary Figure 6: Visualization of structural variants in cfDNA
Supplementary Tables 1-4 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Authors: George Suzanne , Heinrich Michael C. , Somaiah Neeta , Oppelt Peter , McLeod Robert , Nishioka Satoshi , Kundu Madan G. , Qian Xiaozhong , Kumar Prasanna , Laadem Abderrahmane , Lau Yvonne , Tran Brittany P. , Fallon Maura , Dosunmu Ololade , Shi Julia , Naito Yoichi
Published: September 2023

Supplementary Tables 1-4
Supplementary Figure S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Authors: Lheureux Stephanie , Prokopec Stephenie D. , Oldfield Leslie E. , Gonzalez-Ochoa Eduardo , Bruce Jeffrey P. , Wong Derek , Danesh Arnavaz , Torti Dax , Torchia Jonathan , Fortuna Alexander , Singh Sharanjit , Irving Matthew , Marsh Kayla , Lam Bernard , Speers Vanessa , Yosifova Aleksandra , Oaknin Ana , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , Oza Amit M. , Pugh Trevor J.
Published: September 2023

Supplementary Figure 3: Distribution of ctDNA levels and statistical association with clinical features
Supplementary Figure S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Authors: Lheureux Stephanie , Prokopec Stephenie D. , Oldfield Leslie E. , Gonzalez-Ochoa Eduardo , Bruce Jeffrey P. , Wong Derek , Danesh Arnavaz , Torti Dax , Torchia Jonathan , Fortuna Alexander , Singh Sharanjit , Irving Matthew , Marsh Kayla , Lam Bernard , Speers Vanessa , Yosifova Aleksandra , Oaknin Ana , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , Oza Amit M. , Pugh Trevor J.
Published: September 2023

Supplementary Figure 2: Estimated tumour content in plasma DNA
Supplementary Tables S1-S9 from A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma
Authors: Lee Yun Bin , Nam Joon Yeul , Cho Eun Ju , Lee Jeong-Hoon , Yu Su Jong , Kim Hyo-Cheol , Paeng Jin Chul , Yoon Jung-Hwan , Kim Yoon Jun
Published: September 2023

Supplementary Tables S1-S9
Supplementary Figure S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Authors: Lheureux Stephanie , Prokopec Stephenie D. , Oldfield Leslie E. , Gonzalez-Ochoa Eduardo , Bruce Jeffrey P. , Wong Derek , Danesh Arnavaz , Torti Dax , Torchia Jonathan , Fortuna Alexander , Singh Sharanjit , Irving Matthew , Marsh Kayla , Lam Bernard , Speers Vanessa , Yosifova Aleksandra , Oaknin Ana , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , Oza Amit M. , Pugh Trevor J.
Published: September 2023

Supplementary Figure 1: Establishment of limit of detection (LOD) for targeted sequencing panel on ctDNA
Supplementary Table S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Authors: Derry Jonathan M.J. , Burns Connor , Frazier Jason P. , Beirne Emily , Grenley Marc , DuFort Christopher C. , Killingbeck Emily , Leon Michael , Williams Claire , Gregory Mark , Houlton Jeffrey , Clayburgh Daniel , Swiecicki Paul , Huszar Dennis , Berger Allison , Klinghoffer Richard A.
Published: September 2023

GeoMx ROI Information
Supplementary Table S4 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Authors: Derry Jonathan M.J. , Burns Connor , Frazier Jason P. , Beirne Emily , Grenley Marc , DuFort Christopher C. , Killingbeck Emily , Leon Michael , Williams Claire , Gregory Mark , Houlton Jeffrey , Clayburgh Daniel , Swiecicki Paul , Huszar Dennis , Berger Allison , Klinghoffer Richard A.
Published: September 2023

Patient Demographics
Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Authors: Alsadhan Anfal , Chen Jonathan , Gaglione Erika M. , Underbayev Chingiz , Tuma Pamela L. , Tian Xin , Freeman Lita A. , Baskar Sivasubramanian , Nierman Pia , Soto Susan , Itsara Andy , Ahn Inhye E. , Sun Clare , Bibikova Elena , Hartmann Tanja Nicole , Mhibik Maissa , Wiestner Adrian
Published: September 2023

Supplementary Table S8. DEGs for 6 months Comparison of CD49d+ and CD49d-
Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Authors: Alsadhan Anfal , Chen Jonathan , Gaglione Erika M. , Underbayev Chingiz , Tuma Pamela L. , Tian Xin , Freeman Lita A. , Baskar Sivasubramanian , Nierman Pia , Soto Susan , Itsara Andy , Ahn Inhye E. , Sun Clare , Bibikova Elena , Hartmann Tanja Nicole , Mhibik Maissa , Wiestner Adrian
Published: September 2023

Supplementary Table S7. DEGs for 1 month Comparison of CD49d+ and CD49d-
Supplementary Figure S7 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Authors: Derry Jonathan M.J. , Burns Connor , Frazier Jason P. , Beirne Emily , Grenley Marc , DuFort Christopher C. , Killingbeck Emily , Leon Michael , Williams Claire , Gregory Mark , Houlton Jeffrey , Clayburgh Daniel , Swiecicki Paul , Huszar Dennis , Berger Allison , Klinghoffer Richard A.
Published: September 2023

FOV placement for SMI Analysis for Patients 7 and 8 showing variation between sampled regions of the tumor
Supplementary Figure S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Authors: Derry Jonathan M.J. , Burns Connor , Frazier Jason P. , Beirne Emily , Grenley Marc , DuFort Christopher C. , Killingbeck Emily , Leon Michael , Williams Claire , Gregory Mark , Houlton Jeffrey , Clayburgh Daniel , Swiecicki Paul , Huszar Dennis , Berger Allison , Klinghoffer Richard A.
Published: September 2023

Subasumstat dependent decrease in cell cycle signature observed across the tumor sample set by DSP
Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Authors: Alsadhan Anfal , Chen Jonathan , Gaglione Erika M. , Underbayev Chingiz , Tuma Pamela L. , Tian Xin , Freeman Lita A. , Baskar Sivasubramanian , Nierman Pia , Soto Susan , Itsara Andy , Ahn Inhye E. , Sun Clare , Bibikova Elena , Hartmann Tanja Nicole , Mhibik Maissa , Wiestner Adrian
Published: September 2023

Supplementary Table S10. Outcome Data
Supplementary Figure S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Authors: Alsadhan Anfal , Chen Jonathan , Gaglione Erika M. , Underbayev Chingiz , Tuma Pamela L. , Tian Xin , Freeman Lita A. , Baskar Sivasubramanian , Nierman Pia , Soto Susan , Itsara Andy , Ahn Inhye E. , Sun Clare , Bibikova Elena , Hartmann Tanja Nicole , Mhibik Maissa , Wiestner Adrian
Published: September 2023

Supplementary Figure S5. Time to disease progression, prevalence of resistance mutations, and risk category by CLL-4 model
Supplementary Figure S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Authors: Alsadhan Anfal , Chen Jonathan , Gaglione Erika M. , Underbayev Chingiz , Tuma Pamela L. , Tian Xin , Freeman Lita A. , Baskar Sivasubramanian , Nierman Pia , Soto Susan , Itsara Andy , Ahn Inhye E. , Sun Clare , Bibikova Elena , Hartmann Tanja Nicole , Mhibik Maissa , Wiestner Adrian
Published: September 2023

Supplementary Figure S4. Clinical impact of CD49d bimodal expression on durability of BTKi therapy.
Supplementary Figure S16 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Authors: Derry Jonathan M.J. , Burns Connor , Frazier Jason P. , Beirne Emily , Grenley Marc , DuFort Christopher C. , Killingbeck Emily , Leon Michael , Williams Claire , Gregory Mark , Houlton Jeffrey , Clayburgh Daniel , Swiecicki Paul , Huszar Dennis , Berger Allison , Klinghoffer Richard A.
Published: September 2023

Percentage of each of three macrophage populations in individual FOVS from Patient 8
Supplementary Figure S14 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Authors: Derry Jonathan M.J. , Burns Connor , Frazier Jason P. , Beirne Emily , Grenley Marc , DuFort Christopher C. , Killingbeck Emily , Leon Michael , Williams Claire , Gregory Mark , Houlton Jeffrey , Clayburgh Daniel , Swiecicki Paul , Huszar Dennis , Berger Allison , Klinghoffer Richard A.
Published: September 2023

Subasumstat induces changes in the TME associated with Interferon Signature expression
Supplementary Figure S1 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Authors: Alsadhan Anfal , Chen Jonathan , Gaglione Erika M. , Underbayev Chingiz , Tuma Pamela L. , Tian Xin , Freeman Lita A. , Baskar Sivasubramanian , Nierman Pia , Soto Susan , Itsara Andy , Ahn Inhye E. , Sun Clare , Bibikova Elena , Hartmann Tanja Nicole , Mhibik Maissa , Wiestner Adrian
Published: September 2023

Supplementary Figure S1. Tumor volume in CD49d+ and CD49d− CLL during acalabrutinib treatment
Supplementary Figure S13 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Authors: Derry Jonathan M.J. , Burns Connor , Frazier Jason P. , Beirne Emily , Grenley Marc , DuFort Christopher C. , Killingbeck Emily , Leon Michael , Williams Claire , Gregory Mark , Houlton Jeffrey , Clayburgh Daniel , Swiecicki Paul , Huszar Dennis , Berger Allison , Klinghoffer Richard A.
Published: September 2023

TME cell spatial distributions in Patient 7 and Patient 8
Supplementary Figure S4 from Evaluation of Somatic Mutations in Urine Samples as a Noninvasive Method for the Detection and Molecular Classification of Endometrial Cancer
Authors: Costas Laura , Onieva Irene , Pelegrina Beatriz , Marin Fátima , Carmona Álvaro , López-Querol Marta , Frias-Gomez Jon , Peremiquel-Trillas Paula , Martínez José Manuel , Dorca Eduard , Brunet Joan , Pineda Marta , Ponce Jordi , Matias-Guiu Xavier , de Sanjosé Silvia , Bosch Francesc Xavier , Alemany Laia , Paytubi Sonia
Published: September 2023

ROC curve showing the detection performance of the NGS test in supernatant urine samples
Supplementary Figure S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Authors: Derry Jonathan M.J. , Burns Connor , Frazier Jason P. , Beirne Emily , Grenley Marc , DuFort Christopher C. , Killingbeck Emily , Leon Michael , Williams Claire , Gregory Mark , Houlton Jeffrey , Clayburgh Daniel , Swiecicki Paul , Huszar Dennis , Berger Allison , Klinghoffer Richard A.
Published: September 2023

Subasumstat Target Engagement Grading by MIL113 Staining
Supplementary Tables 1-8 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Authors: Salari Keyan , Sundi Debasish , Lee Jason J. , Wu Shulin , Wu Chin-Lee , DiFiore Gabrielle , Yan Q. Robert , Pienkny Andrew , Lee Chi K. , Oberlin Daniel , Barme Greg , Piser Joel , Kahn Robert , Collins Edward , Phillips Kevin G. , Caruso Vincent M. , Goudarzi Mahdi , Garcia-Ransom Monica , Lentz Peter S. , Evans-Holm Martha E. , MacBride Andrew R. , Fischer Daniel S. , Haddadzadeh Iden J. , Mazzarella Brian C. , Gray Joe W. , Koppie Theresa M. , Bicocca Vincent T. , Levin Trevor G. , Lotan Yair , Feldman Adam S.
Published: September 2023

Supplemental Tables 1-8
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
Authors: Vieito Maria , Moreno Victor , Spreafico Anna , Brana Irene , Wang Judy S. , Preis Meir , Hernández Tatiana , Genta Sofia , Hansen Aaron R. , Doger Bernard , Galvao Vladimir , Lenox Laurie , Brown Regina J. , Kalota Anna , Mehta Jaydeep , Pastore Friederike , Patel Bharvin , Mistry Pankaj , Gu Junchen , Lauring Josh , Patel Manish R.
Published: September 2023

Supplementary Tables 1-3
Supplementary Figure 1 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Authors: Salari Keyan , Sundi Debasish , Lee Jason J. , Wu Shulin , Wu Chin-Lee , DiFiore Gabrielle , Yan Q. Robert , Pienkny Andrew , Lee Chi K. , Oberlin Daniel , Barme Greg , Piser Joel , Kahn Robert , Collins Edward , Phillips Kevin G. , Caruso Vincent M. , Goudarzi Mahdi , Garcia-Ransom Monica , Lentz Peter S. , Evans-Holm Martha E. , MacBride Andrew R. , Fischer Daniel S. , Haddadzadeh Iden J. , Mazzarella Brian C. , Gray Joe W. , Koppie Theresa M. , Bicocca Vincent T. , Levin Trevor G. , Lotan Yair , Feldman Adam S.
Published: September 2023

Supplementary Figure 1. Genomic profiles of the validation cohort.
Supplementary Table S1 from Driving Diversity and Inclusion in Cancer Drug Development – Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges
Authors: Fashoyin-Aje Lola A. , Tendler Craig , Lavery Bea , Ghiorghiu Serban , Gerald Brittany , Kalidas Chitkala , Richie Nicole , Winson Kathleen , Warren Nicholas J.H. , Tellman Tristen V. , Retzlaff Jon , Foti Margaret , Pazdur Richard
Published: September 2023

Diversity Plan Guidance Framework
Supplementary Table S3 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Authors: Gadgeel Shirish M. , Miao Jieling , Riess Jonathan W. , Moon James , Mack Philip C. , Gerstner Gregory J. , Burns Timothy F. , Taj Asma , Akerley Wallace L. , Dragnev Konstantin H. , Laudi Noel , Redman Mary W. , Gray Jhanelle E. , Gandara David R. , Kelly Karen
Published: September 2023

Supplementary Table 3. Patient Characteristics for those with and without assay results
Supplementary Table S2 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Authors: Gadgeel Shirish M. , Miao Jieling , Riess Jonathan W. , Moon James , Mack Philip C. , Gerstner Gregory J. , Burns Timothy F. , Taj Asma , Akerley Wallace L. , Dragnev Konstantin H. , Laudi Noel , Redman Mary W. , Gray Jhanelle E. , Gandara David R. , Kelly Karen
Published: September 2023

Supplementary Table 2. Representativeness of Study Participants
Data from Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages
Authors: Yuan Wei , Zhang Qian , Gu Danling , Lu Chenfei , Dixit Deobrat , Gimple Ryan C. , Gao Yisu , Gao Jiancheng , Li Daqi , Shan Danyang , Hu Lang , Li Lu , Li Yangqing , Ci Shusheng , You Hao , Yan Linping , Chen Kexin , Zhao Ningwei , Xu Chuanhai , Lan Jianyun , Liu Dong , Zhang Junxia , Shi Zhumei , Wu Qiulian , Yang Kailin , Zhao Linjie , Qiu Zhixin , Lv Deguang , Gao Wei , Yang Hui , Lin Fan , Wang Qianghu , Man Jianghong , Li Chaojun , Tao Weiwei , Agnihotri Sameer , Qian Xu , Mack Stephen C. , Zhang Nu , You Yongping , Rich Jeremy N. , Sun Guan , Wang Xiuxing
Published: September 2023

AbstractPurpose:
The dynamic interplay between glioblastoma stem cells (GSC) and tumor-associated macrophages (TAM) sculpts the tumor immune microenvironment (TIME) and promotes malignant progression of glioblastoma (GBM). However, the mechanisms underlying this interaction are still incompletely understood. Here, we investigate the role of CXCL8 in the maintenance of the mesenchymal state of GSC populations and reprogramming the TIME to an immunosuppressive state.
Experimental Design:
We performed an integrative multi-omics analyses of RNA sequencing, GBM mRNA expression datasets, immune signatures, and epigenetic profiling to define the specific genes expressed in the mesenchymal GSC subsets. We then used patient-derived GSCs and a xenograft murine model to investigate the mechanisms of tumor-intrinsic and extrinsic factor to maintain the mesenchymal state of GSCs and induce TAM polarization.
Results:
We identified that CXCL8 was preferentially expressed and secreted by mesenchymal GSCs and activated PI3K/AKT and NF-κB signaling to maintain GSC proliferation, survival, and self-renewal through a cell-intrinsic mechanism. CXCL8 induced signaling through a CXCR2–JAK2/STAT3 axis in TAMs, which supported an M2-like TAM phenotype through a paracrine, cell-extrinsic pathway. Genetic- and small molecule–based inhibition of these dual complementary signaling cascades in GSCs and TAMs suppressed GBM tumor growth and prolonged survival of orthotopic xenograft-bearing mice.
Conclusions:
CXCL8 plays critical roles in maintaining the mesenchymal state of GSCs and M2-like TAM polarization in GBM, highlighting an interplay between cell-autonomous and cell-extrinsic mechanisms. Targeting CXCL8 and its downstream effectors may effectively improve GBM treatment.
Data from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
Authors: Tovey Holly , Sipos Orsolya , Parker Joel S. , Hoadley Katherine A. , Quist Jelmar , Kernaghan Sarah , Kilburn Lucy , Salgado Roberto , Loi Sherene , Kennedy Richard D. , Roxanis Ioannis , Gazinska Patrycja , Pinder Sarah E. , Bliss Judith , Perou Charles M. , Haider Syed , Grigoriadis Anita , Tutt Andrew , Cheang Maggie Chon U.
Published: September 2023

AbstractPurpose:
The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation subgroup. Broader response-predictive biomarkers are needed. We explored the predictive ability of DNA damage response (DDR) and immune markers.
Experimental Design:
Tumor-infiltrating lymphocytes were evaluated for 222 of 376 patients. Primary tumors (PT) from 186 TNT participants (13 matched recurrences) were profiled using total RNA sequencing. Four transcriptional DDR-related and 25 immune-related signatures were evaluated. We assessed their association with objective response rate (ORR) and progression-free survival (PFS). Conditional inference forest clustering was applied to integrate multimodal data. The biology of subgroups was characterized by 693 gene expression modules and other markers.
Results:
Transcriptional DDR-related biomarkers were not predictive of ORR to either treatment overall. Changes from PT to recurrence were demonstrated; in chemotherapy-naïve patients, transcriptional DDR markers separated carboplatin responders from nonresponders (P values = 0.017; 0.046). High immune infiltration was associated with docetaxel ORR (interaction P values < 0.05). Six subgroups were identified; the immune-enriched cluster had preferential docetaxel response [62.5% (D) vs. 29.4% (C); P = 0.016]. The immune-depleted cluster had preferential carboplatin response [8.0% (D) vs. 40.0% (C); P = 0.011]. DDR-related subgroups were too small to assess ORR.
Conclusions:
High immune features predict docetaxel response, and high DDR signature scores predict carboplatin response in treatment-naïve mTNBC. Integrating multimodal DDR and immune-related markers identifies subgroups with differential treatment sensitivity. Treatment options for patients with immune-low and DDR-proficient tumors remains an outstanding need. Caution is needed using PT-derived transcriptional signatures to direct treatment in mTNBC, particularly DDR-related markers following prior chemotherapy.
Abstract IA03: Head and Neck Cancer Takes a Nerve, Cancer neuroscience: emerging hallmark of cancer
Authors: Amit Moran
Published: September 2023

Over the past decade, emerging technologies have enabled investigators to begin to bridge the gap between cancer and neuroscience research to unveil the interactive roles of nerves in cancer. We are now beginning to define how the nervous system contributes to cancer initiation, growth, spread, recurrence, and even resistance to oncologic therapeutic strategies. Indeed, neuromodulation with both genetic and pharmacological approaches has been shown to affect not only tumor growth but also antitumor immune response. Collectively, studies have demonstrated a significant and pressing need to recognize cancer neuroscience interplay as a hallmark of cancer to 1) establish the neoneurogenic process as a highly relevant therapeutic target for both the prevention and treatment of cancer, 2) foster interdisciplinary cross-talk among experts in cancer biology and neuroscience, which have traditionally progressed along parallel paths, and 3) integrate human variables such as biological sex, age, race, and gender as underlying factors that can impact cancer neuroscience.

Citation Format: Moran Amit. Head and Neck Cancer Takes a Nerve, Cancer neuroscience: emerging hallmark of cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr IA03.
Abstract PO-023: The AP-1 transcription factor component, JunB, regulates the expression of HPV genes in head and neck cancer
Authors: Rehmani Hina , Isaeva Natalia , Schrank Travis P. , Yarbrough Wendell G.
Published: September 2023

Within head and neck squamous cell carcinoma (HNSCC), those induced by the human papillomavirus (HPV+) have a more hypermethylated genome compared to those that are negative (HPV-). Therefore, our lab explored the usage of the demethylating agent 5-azacytidine (5-aza), an FDA-approved drug for the treatment of myelodysplasia and acute myeloid leukemia. Repurposing FDA-approved drugs is a strategic way to quickly provide patients with secondary therapeutic options, especially since the incidence of HPV+ HNSCC is now considered an epidemic in the US and Western Europe. Additionally, initial therapy for patients is aggressive leading to adverse, lifelong side effects. Despite having a higher cure rate than HPV-HNSCC, the recurrence rate is still approximately 30% for HPV+ HNSCC. Our lab has found that HPV+ HNSCC cells are more sensitive than HPV- cells to 5-aza as low doses of 5-aza delayed HPV+ xenograft tumor growth and 5-aza-treated HPV+ tumor samples from patients treated in a window trial had increased cell death. Despite demethylation inducing an active, open chromatin conformation, we also observed a marked downregulation of HPV genes expression after 5-aza. Decreased HPV E6 expression, followed by reactivation of tumor suppressor p53, induced p53-dependent apoptosis in HPV+ HNSCC. This decreased expression of HPV genes is an essential component of 5-aza-associated toxicity toward HPV+ HNSCC. Our lab has recently explored the molecular mechanisms of 5-aza on HPV+ HNSCC. We found that 5-aza transcriptionally downregulated the expression of HPV genes, including oncogenes E6 and E7. Microarray studies show marked downregulation of the proto-oncogene JunB, a component of the transcription factor AP-1 (Activator Protein 1) after 5-aza treatment. Experimental deletion of JunB inhibited oncogenes E6 and E7 and restored p53 but also indicated that untreated HPV+ HNSCCs depend on JunB for clonogenic growth. Through this study, we have identified a novel dependency on JunB in HPV+ HNSCC and revealed a new rational target that is desperately needed to treat recurrent/metastatic patients and decrease the toxicity associated with current treatment.

Citation Format: Hina Rehmani, Natalia Isaeva, Travis P. Schrank, Wendell G. Yarbrough. The AP-1 transcription factor component, JunB, regulates the expression of HPV genes in head and neck cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-023.
Abstract PO-080: Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma
Authors: Kwon Minsu , Lee Yoon Se , Jung Hanul , Kim Min Ji , Kang So Hee , Seo Ji-Hyun , Park Jung Je
Published: September 2023

The purpose of this study was to determine whether statins can enhance anticancer effects in head and neck squamous cell carcinoma (HNSCC) when used with cisplatin and act as immunogenic cell death (ICD) inducers that can be used in cancer immunotherapy. Statins alone showed both in vitro and in vivo inhibitory effects against HNSCC, and synergistic antitumor effects were observed when combined with cisplatin in a syngeneic murine HNSCC model. Statins increased calreticulin exposure and endoplasmic reticulum stress-related signals in HNSCC cells. In addition, it was confirmed that statins could activate antigen-presenting cells and tumor-specific CD8+ T cells with an increase in their numbers in the tumor tissues and draining lymph nodes, with this effect showing significant improvement following the combination therapy with cisplatin. Moreover, in triple combination with both cisplatin and anti-programmed cell death 1 receptor (anti-PD-1) antibody, statins dramatically induced further tumor eradication and improved the survival of tumor-bearing mice. Taken together, these results demonstrate that statins, administered in combination with anti-PD-1 antibody, could enhance the anticancer effect of cisplatin and potentiate the efficacy of immunotherapy for HNSCC and present a rationale for repurposing statins as an adjuvant immunotherapeutic option for HNSCC.

Citation Format: Minsu Kwon, Yoon Se Lee, Hanul Jung, Min Ji Kim, So Hee Kang, Ji-Hyun Seo, Jung Je Park. Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-080.
Abstract PO-091: Leveraging tissue-resident CD103+ NK cells for adoptive cell therapy in head and neck cancer
Authors: Horowitz Nina B. , Shin June Ho , Maddineni Sainiteesh , Mohammad Imran A. , Liu Alice Xinyuan , Sunwoo John B.
Published: September 2023

A major obstacle for all cell therapy of solid tumors has been the ability of adoptively transferred cells to infiltrate into immunosuppressive solid tumor microenvironments. In this study, we developed a method of differentiating and expanding a novel subset of tissue-resident natural killer (NK) cells and assessed their capacity to infiltrate head and neck squamous cell carcinoma (HNSCC) and control tumor growth in vivo. In previous work, single-cell RNA sequencing was performed to profile the entire innate lymphoid cell (ILC) family of lymphocytes (including NK cells) isolated from primary human head and neck squamous cell carcinoma (HNSCC). This revealed multiple subsets of NK cell and ILC states within the tumors. A particular NK cell state, resembling intraepithelial ILC1s (ieILC1), expressed integrins characteristic of tissue residency (such as CD103) and expressed the highest levels of granzyme A, granzyme B, and perforin, suggesting potent cytolytic activity. In the current study, we investigated the potential of these cells for adoptive cell immunotherapy against solid tumors, such as HNSCC and melanoma. Using a co-culture system, we developed a method to differentiate and expand a highly purified population of human CD103+ ieILC1-like NK cells ex vivo to clinically relevant numbers. In vitro impedance-based killing assays were used to assess and demonstrate that these cells have superior cytolytic activity against a variety of epithelial target cells, compared to conventional NK cells. In vivo mouse models using xenografts of HNSCC and melanoma in NSG mice were used to assess and demonstrate superior capacity of ieILC1-like NK cells to control tumor growth compared to conventional NK cells from the same donor. Importantly, the CD103+ ieILC1-like NK cells were able to infiltrate the tumor microenvironment significantly better than conventional NK cells, which likely contributed to their potent control of tumors in vivo. Thus, these findings introduce a novel subset of immune cells that have efficient tumor-infiltrating capacity and potent cytolytic activity for adoptive cell therapy of solid tumors. Because conventional NK cells have already demonstrated clinical activity, these preclinical data indicate that CD103+ ieILC1-like NK cells warrant investigation in the clinic.

Citation Format: Nina B. Horowitz, June Ho Shin, Sainiteesh Maddineni, Imran A. Mohammad, Alice Xinyuan Liu, John B. Sunwoo. Leveraging tissue-resident CD103+ NK cells for adoptive cell therapy in head and neck cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-091.
Abstract PR07: Oncogene addition to MYB-NFIB in adenoid cystic carcinomas induced in transgenic mice
Authors: Escamilla-Rivera Vicente , Hu Yuan , Cho Sungman , El-Naggar Adel , Luo Han , Caulin Carlos
Published: September 2023

Adenoid cystic carcinoma (ACC) is a slow-growing salivary gland malignancy. The frequent occurrence of chromosome t(6;9) translocations, resulting in MYB-NFIB fusions, is a hallmark of ACC. Approximately, 50% of all ACCs studied to date have been shown to express MYB-NFIB chimeric transcripts, suggesting a prominent role in ACC tumorigenicity. However, the potential relevance of chimeric MYB-NFIB proteins in the development and progression of ACC remains poorly understood. To assess the role of MYB-NFIB in ACC development, we generated transgenic mice in which MYB-NFIB is overexpressed in salivary and mammary glands, using a doxycycline-inducible system. Importantly, a subset of these mice developed ACCs, suggesting that MYB-NFIB is an oncogenic driver of ACC. Using this reversible inducible model, we investigated whether MYB-NFIB was required to maintain established tumors. We found that suppression of the MYB-NFIB transgene upon exposure to doxycycline (Dox) promoted a rapid tumor regression. Tumoral volumes decreased by more than 50 % after only 10 days of starting Dox. This reduction in volume was accompanied by a transition towards a more organized cellular structure and a reduction in the number of cells positive for Ki-67 and MYB-NFIB. To identify mechanisms involved in tumor regression, we compared the transcriptomes from biopsies collected from salivary tumors prior to MYB-NFIB suppression with those from the same tumors after Dox-induced regression. We found that tumor regression upregulated immune-related pathways and promoted T cell infiltration. Additionally, several pathways were downregulated by MYB-NFIB suppression; particularly NOTCH signaling, Cyclin D1-CDK4/6, and Wnt/beta-catenin signaling. We then confirmed, by immunohistochemistry, that tumor biopsies taken before Dox had a higher number of cells positive for Cdk6, CyclinD1, and nuclear beta-catenin. Our results suggest that proteins in these pathways could be used as potential therapeutic targets in MYB-NFIB-driven ACCs.

Citation Format: Vicente Escamilla-Rivera, Yuan Hu, Sungman Cho, Adel El-Naggar, Han Luo, Carlos Caulin. Oncogene addition to MYB-NFIB in adenoid cystic carcinomas induced in transgenic mice [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PR07.
Supplementary Table S9 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
Authors: Sato Shinya , Nakagawa Masatoshi , Terashima Takeshi , Morinaga Soichiro , Miyagi Yohei , Yoshida Eisaku , Yoshimura Toru , Seiki Motoharu , Kaneko Shuichi , Ueno Makoto , Yamashita Taro , Koshikawa Naohiko
Published: September 2023

Median survival time of PC patients treated with GnP (G) and mFFX (F) classified into CA19-9 high (≥37 U / ml) and low (<37 U / ml) groups.
Supplementary Table S7 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
Authors: Sato Shinya , Nakagawa Masatoshi , Terashima Takeshi , Morinaga Soichiro , Miyagi Yohei , Yoshida Eisaku , Yoshimura Toru , Seiki Motoharu , Kaneko Shuichi , Ueno Makoto , Yamashita Taro , Koshikawa Naohiko
Published: September 2023

Median survival time of PC patients treated with surgical resection and chemotherapy after classification into serum CA19-9 high (≥37 U / ml) and low (<37 U / ml) groups.
Atoms for Peace in the 1950s: Lessons from the Spread of Nuclear Technology in the Early Cold War
Authors: Josephson Paul R.
Published: September 2023

The articles in this special issue shed light on the influence of the Eisenhower administration's “Atoms for Peace” proposal on the civilian nuclear programs of five European countries, including Italy and France, which were member-states of the North Atlantic Treaty Organization (NATO); Hungary and Czechoslovakia, which were part of the USSR's Communist bloc; and Spain, which did not become a member of NATO until nearly three decades later. Based on detailed archival research, the articles analyze the commercial, scientific, practical, and cultural aspects of nascent nuclear research programs in these five countries. The authors demonstrate that all five acted early on to pursue peaceful nuclear activities for their own economic benefit.
Constructing Nuclear Culture under Soviet-Style Communism: The Hungarian Experience
Authors: Palló Gábor , Adamson Matthew
Published: September 2023

In the mid-1950s, Atoms for Peace provided a crucial boost for the study of nuclear physics in Hungary, a country that fell under Communist rule and Soviet domination after World War II. Several small, insulated centers of nuclear research already existed, but after President Dwight Eisenhower's speech to the United Nations General Assembly on 3 December 1953, calling for the development of Atoms for Peace programs, Hungary's efforts began to grow quickly. In the glow of the moment, with significant support from the government and the ruling Communist party, Hungarian physicists established new research centers, bought and constructed instruments, published specialized books and journals, held conferences, and organized university courses and programs to train experts both at home and in the USSR. These activities constituted a new, vibrant nuclear culture encompassing diverse areas of life (agriculture, medicine, and some parts of industry) and eventually some cooperative links with Western and Soviet-bloc scientific communities.
Evidence of Impaired Remote Experience-near Semantic Memory in Medial Temporal Lobe Amnesia
Authors: Grilli Matthew D. , Sabharwal-Siddiqi Sameer , Thayer Sean C. , Rapcsak Steven Z. , Ekstrom Arne D.
Published: September 2023

Neuropsychological research suggests that “experience-near” semantic memory, meaning knowledge attached to a spatiotemporal or event context, is commonly impaired in individuals who have medial temporal lobe amnesia. It is not known if this impairment extends to remotely acquired experience-near knowledge, which is a question relevant to understanding hippocampal/medial temporal lobe functioning. In the present study, we administered a novel semantic memory task designed to target knowledge associated with remote, “dormant” concepts, in addition to knowledge associated with active concepts, to four individuals with medial temporal lobe amnesia and eight matched controls. We found that the individuals with medial temporal lobe amnesia generated significantly fewer experience-near semantic memories for both remote concepts and active concepts. In comparison, the generation of abstract or “experience-far” knowledge was largely spared in the individuals with medial temporal lobe amnesia, regardless of whether the targets for retrieval were remote or active concepts. We interpret these findings as evidence that the medial temporal lobes may have a sustained role in the retrieval of semantic memories associated with spatiotemporal and event contexts, which are cognitive features often ascribed to episodic memory. These results align with recent theoretical models proposing that the hippocampus/medial temporal lobes support cognitive processes that are involved in, but not exclusive to, episodic memory.
Verbal Abilities: Sex Differences in Children at Different Ages
Authors: Rzhanova Irina E. , Alekseeva Olga S. , Boldyreva Anna Ya. , Nikolaeva Anastasia Yu. , Burdukova Yulia A.
Published: September 2023

Background. The assertion of sex differences in verbal abilities is a highly controversial subject. Some studies have demonstrated a female advantage; other studies have found higher rates in males. The results depended on the type of verbal ability that was studied, the cultural context, and the ages of the subjects. There are two types of theories that have been developed to explain the existence of sex differences in cognitive abilities. Social theories explain the differences as caused by social determinants. Biological theories consider biological factors such as prenatal development conditions and hormone levels, among others, as the cause of sex differences. Objective. To investigate sex differences in verbal abilities in children of different ages. Design. Two different editions of Wechsler tests were used. For children age 2.5 to 5 years, the Wechsler Preschool Primary Scale of Intelligence (WPPSI-IV) was used. For children age 6 and older, we administered the Wechsler Intelligence Scale for Children (WISC-V). The total sample included 313 children. Results. The study found significant sex differences in performance on the Verbal Comprehension Scale in children of different ages. At the age of 2 to 4 years, the girls performed better than the boys. In the group of boys, there was a significant increase in verbal abilities at the age of 8–9 years. By the age of 10–11 years, boys began outperforming girls on the Verbal Comprehension Index. Scores on the Verbal Comprehension and Visual Spatial subtests for the boy sample showed stronger correlations than in the girl sample in all age groups. Conclusion. Sex differences in verbal abilities varied depending on the age of the children. The boys showed a stronger integration of their verbal abilities into the structure of their intelligence than the girls.
Toy Preferences among 3-to-4-Year-Old Children: The Impact of Socio-Demographic Factors and Developmental Characteristics
Authors: Gavrilova Margarita N. , Sukhikh Vera L. , Veresov Nikolay N.
Published: September 2023

Background. Today’s common typologies and categories of children’s toys are mainly decided by the manufacturers and retailers of children's products. Such categorizations are not based on a theoretical understanding of child development and therefore cannot provide information about the opportunities that toys provide for the young. Objective. This study proposed three criteria for categorizing toys based on the cultural-historical approach: their degree of realism; their degree of anthropomorphism; and their degree of detail. These criteria were chosen as a result of an analysis of theoretical works carried out in the framework of cultural-historical approach. Design. The proposed criteria were tested through an experiment measuring children's toy preferences. The participants were 129 children of ages 3-4 years. Experimental data confirmed that most children do prefer realistic and detailed toys rather than those with fewer of these properties. The contribution of socio-demographic factors and the children’s individual developmental indicators to their toy preference was also analyzed. Results. The study revealed that among various socio-demographic factors, only the child’s gender and the number of siblings in the family acted as significant predictors for the toy preferences. None of child's developmental characteristics (non-verbal intelligence, executive functions, and emotional understanding) were found to be significant predictors of preference for particular toys. Conclusions. The assumption that toys can be assessed in terms of their realism and degree of detail found empirical support. The results of this study may be useful in designing further research and in the practical issue of toy selection for children age 3-4 years.
IKS and Gendered Ecologies
Authors: Human Christina , Cawood Stephanie , van As Liesl L.
Published: September 2023

Two geological fault lines mark the southernmost tip of the Great East African Rift Valley. An ancient tectonic uplift, or superswell, caused rifting down the spine of the African continent, which created the Okavango Delta, an endorheic (enclosed) wetland in Botswana. The huge and biodiverse waterbody is an anomaly, as it is surrounded by the otherwise arid Kalahari Desert. Part of this delta is known as the Panhandle. Despite evidence of the Anthropocene, the area teems with massive concentrations of wildlife. It is also home to a diverse post/colonial concentration of human inhabitants, some Indigenous. Each segment of this population has a unique relationship with the environment, informed by Indigenous knowledge systems (IKS), geopolitical hierarchies and the misogynistic politics of the post/colonial nation-state in which hegemonic patriarchies produce gendered ecologies. Through a breaking rank methodology, this paper explores the gendered ecologies and IKS of the post/colonial Panhandle community.
I-It Versus I-Thou Science and Society: Introduction to Special Feature on Maslow’s (1969) “Toward a Humanistic Biology”
Authors: Bland Andrew M.
Published: September 2023

This special feature centers around Journal of Humanistic Psychology co-founder Abraham Maslow’s 1969 article, “Toward a Humanistic Biology.” My aims for this special feature are to showcase perspectives on and responses to Maslow’s article from the vantage point of the early 2020s by multiple generations and iterations of humanistic psychologists. This serves not only to challenge misconceptions of Maslow—and humanistic psychology in general—as a mere historical relic but also to continue updating and contextualizing our foundational canon to make it relevant to new and future generations while also preserving, and without losing sight of, its core and the wisdom of our elders. In this introduction, following a review of advancements in psychology since Maslow’s day (including some called for in his 1969 article), I summarize key points and themes from the article and discuss their relevance in today’s society. Then, I identify the limitations in and conundrums posed by some of Maslow’s statements. Finally, I provide a narrative of the 12 articles that follow in this special feature.